We evaluated the efficacy of TTI-101 in the AOM-DSS mouse model of colitis-associated CRC and found that TTI-101 markedly reduced colon tumor burden, at least in part, by normalizing the STAT3-driven pro-oncogenic transcriptome in colonic mucosa. Here, STAT3 is linked to colonic neoplasm.